Quantitative molecular methods to monitor the response of CML patients to interferon-α

Bone Marrow Transplantation

Volumn 17, Issue SUPPL. 3, 1996, Pages

  Hochhaus, A ^a,b,c   Lin, F ^b   Reiter, A ^a   Skladny, H ^a   Hehlmann, R ^a   Goldman, J M ^b   Cross, N C P ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

BCR ABL; CML; Interferon ; Quantitative PCR; Quantitative Southern blot; Residual disease

Indexed keywords

ALPHA INTERFERON;

CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; CYTOGENETICS; DRUG MONITORING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING;

ANTINEOPLASTIC AGENTS; CYTOGENETICS; DNA, NEOPLASM; GENES, ABL; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; POLYMERASE CHAIN REACTION; PROGNOSIS; RNA, NEOPLASM; TIME FACTORS;

EID: 0029953648     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330: 820-825.
2. Hehlmann R, Heimpel H, Hasford J et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia (CML). Blood 1994; 84: 4064-4077.
3. Allan NC, Richards SM, Shepherd PCA. UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet 1995; 345: 1392-1397.
4. Onishi K, Ohno R, Tomonaga M et al. A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995; 86: 906-916.
5. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 1995; 122: 254-261.
6. Hehlmann R, Heimpel H, Hasford J et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia (CML). Prolongation of survival by hydroxyurea. Blood 1993; 82: 398-407.
7. Cross NCP, Hughes TP, Lin F et al. Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: correlations with acute graft-versus-host disease and relapse. Br J Haematol 1993; 84: 67-74.
8. Cross NCP, Lin F, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 82: 1929-1936.
9. Van Rhee F, Marks DI, Lin F et al. Quantification of residual disease in Philadelphia positive acute lymphoblastic leukemia: comparison of blood and bone marrow. Leukemia 1995; 9: 329-335.
10. De Klein A, Hagemeijer A, Bartram CR et al. Bcr rearrangement and translocation of the c-ab1 oncogene in Philadelphia positive acute lymphoblastic leukemia. Blood 1986; 68: 1369-1375.
11. Reiter A, Skladny H, Hochhaus A et al. Manuscript in preparation.
12. ISCN: An international system for human cytogenetic nomenclature. In: Harnden DG, Klinger HP (eds). Basel, Karger, 1985 (Published in collaboration with Cytogen Canc Genet).
13. Hochhaus A, Lin F, Reiter A et al. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-α therapy by competitive polymerase chain reaction. Blood, 1996, 87: 1549-1555.
14. Hook EB. Exclusion of chromosomal mosaicism: tables of 90%, 95% and 99% confidence limits and comments on use. Am J Hum Genet 1977; 29: 94-97.
15. Grossman A, Silver RT, Szatroswki TP, Gutfried A, Verma RS, Benn PA. Densitometric analysis of Southern blot autoradiographs and ist application to monitoring patients with chronic myeloid leukemia. Leukemia 1991; 5: 540-547.
16. Verschraegen CF, Talpaz M. Hirsch-Ginsberg CF et al Quantification of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia. Blood 1995; 85: 2705-2710.
17. Seong DC, Kantarjian HM, Ro JY et al. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood 1995; 86: 2343-2349.
18. Guo JQ, Lian JY, Xian YM et al. BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy. Blood 1994; 83:3629-3637.
19. Hochhaus A, Lin F, Reiter A, et al. Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-α. Br J Haematol 1995; 91: 126-131.
20. Lin F, Chase A, Bungey J, Goldman JM, Cross NCP. Correlation between the proportion of Philadelphia chromosome-positive metaphase cells and levels of BCR-ABL mRNA in chronic myeloid leukaemia. Genes Chrom Canc 1995; 13: 110-114.
21. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995; 86: 3118-3122.
22. Talpaz M, Estrov Z, Kantarjian H, Ku S, Foteh A, Kurzrock R. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. J Clin Invest, 1994; 94: 1383-1389.